Skip to content


  • Commentary
  • Open Access

Avoiding risk at what cost? Putting use of medicines for breastfeeding women into perspective

International Breastfeeding Journal20127:14

  • Received: 27 September 2012
  • Accepted: 15 October 2012
  • Published:


Breastfeeding women often need to take medicines, and therefore health professionals need to consider the effects of medication on lactation and the breastfed infant, and any associated risks. This commentary discusses the tragic case of a young woman with a history of mental illness who committed suicide in the postpartum period. She was determined to be a 'good mother' and breastfeed, and to avoid any potential adverse effects of medication on her breastfed infant. The final outcome was fatal for both mother and child. We argue that if women require medication during lactation, all risks need to be considered – the risk of not treating the maternal medical condition may greatly outweigh the potential risk to the breastfed infant.


  • Breastfeeding
  • Lactation
  • Medication
  • Side-effect
  • Risk
  • Maternal health
  • Postpartum


The death of the brilliant and empathetic young UK psychiatrist who committed suicide in 2000 can have a positive impact on maternal and child health if we learn from the family tragedy[1]. An editorial in The Psychiatrist describing the obstacles experienced by medical professionals seeking and receiving help for mental illness has highlighted this case again[2].

The North East London NHS report on the extended suicide of Dr Daksha Emson, and her three month old daughter, Freya, describes her history of bipolar affective disorder and itemises the potential factors that contributed to the disastrous outcome: immigration, racism, childhood sexual abuse, stigma of mental illness, being a doctor and a patient, and the stresses of pregnancy losses and the postpartum period[3]. She had overcome many obstacles in order to establish her medical career; at times, alternating between hospital admissions and academic prizes.

Dr Emson had stopped her medications when planning a pregnancy, and was reluctant to restart postpartum as she was keen to breastfeed her daughter.

"“Being a good mother by breastfeeding Freya, as Daksha saw it, took such precedence over the need for treatment of her mental illness that she put her mental health at risk. There is a great deal of ignorance about breastfeeding and bipolar affective disorder on the part of professionals and conflicting views by expert witnesses about whether it is safe to breastfeed in conjunction with a mood stabiliser such as lithium carbonate.”[3] p. 19] (our emphasis)."

We shall never know if this double tragedy could have been averted if Dr Emson had been more closely monitored in the risky postpartum period, and if she had recommenced lithium treatment. In the past, lithium was regarded as one of the few medicines contraindicated for breastfeeding women[4]. It was thought the risk to the breastfed infant was too high.

Today, however, clinicians are looking more closely at the compatibility of medicines such as lithium and breastfeeding. Recent guidelines from beyondblue in Australia state that “If the woman chooses to breastfeed, lithium should be used with particular caution. The decision should be made in consultation with a specialist physician and, where possible, there should be ongoing specialist monitoring for potential adverse effects on the breastfed infant."[5] p. 56]. Case series have shown that infants’ lithium concentrations are not as high as previously thought, and if infants’ plasma concentrations are monitored, continued breastfeeding is possible in selected women[6, 7]. Debra Bogen and colleagues have reported three cases of women who successfully breastfed while maintaining lithium treatment[8]. If a woman wishes to breastfeed during lithium therapy, the neonate must be closely observed for dehydration, tremor, involuntary movements, cyanosis, muscle tone and other adverse effects, and monitored by blood tests for lithium concentrations[6, 7]. Supplementary formula feeds should be available in case toxicity is suspected.

The ‘good mother’ discourse asserts that good mothers will breastfeed and avoid any possible contaminants entering their bodies or their breast milk[9]. Health professionals need to challenge this assertion. Good mothers need to look after their own health first, and not compromise their treatment options. Evidence shows that women with mental illnesses are not able to function optimally[5], yet are cautious about taking medicines while breastfeeding because of fear about the effects on their infant or on their ability to breastfeed[10, 11].

The majority of breastfeeding women do take medication[12, 13], as women face both acute illnesses and ongoing medical conditions in the postpartum period. However, the impact on breastfeeding rates, breastfeeding success and infants’ outcomes is largely unknown[1418].

To advise women about the compatibility of medicines and breastfeeding, health professionals need access to accurate information[19]. Information from pharmaceutical companies is usually unnecessarily cautious and should not be relied on. Although more research is urgently needed, clinicians can access information electronically through LactMed[20] and the Perinatal Psychotropic Medicine Information Service[21], as well from information services and books[2224]. Larger studies and long-term follow-up data on child health and school performance, which we are currently lacking, are needed to improve advice for parents[17, 2528]. Another factor limiting clinicians' decision-making about medicines in lactation is that it is almost impossible to access measurement of drug levels in maternal milk or infant blood. Real time access to measurement of drug levels in clinical laboratories would facilitate evidence-based decisions.

Women and their families need to be aware that depression and anxiety are common in the postpartum period. Women may not realise that feelings of exhaustion, sadness, anxiety, loss of appetite and difficulty sleeping may be symptoms of depression and related conditions[5]. Health professionals should discuss these issues with new mothers and offer information, support and treatment options.

Most medicines are safe for breastfeeding women as the breastfed infant would receive less than 3% of a therapeutic dose per kilogram of body weight[25] p. 617], and many medicines are prescribed for neonates themselves. When the decision is not straightforward, clinicians need to consult experienced pharmacists before concluding that breastfeeding and medicine use is too risky. Most decisions won’t be as difficult as prescribing lithium in the peripartum period, but Dr Daksha Emson’s tragic case should teach us that failing to prescribe medicine for a breastfeeding woman could be fatal for both mother and child.



LHA has an Australian National Health and Medical Research Council Career Development Fellowship.

Authors’ Affiliations

Mother & Child Health Research, La Trobe University, Melbourne, VIC, Australia
School of Nursing and Midwifery, La Trobe University, Bundoora, VIC, Australia
Department of Nursing, College of Human and Health Sciences, Swansea University, Swansea, Wales, UK


  1. Emson D: Obitury: Daksha Emson: Formerly Specialist Registrar community and rehabilitation psychiatrist Oxleas NHS Trust, died tragically 27 October 2000. Psychiatrist. 2004, 28: 152-Google Scholar
  2. Garelick AI: Doctors’ health: stigma and the professional discomfort in seeking help. Psychiatrist. 2012, 36: 81-84. 10.1192/pb.bp.111.037903.View ArticleGoogle Scholar
  3. Report of an independent inquiry into the care and treatment of Daksha Emson M.B.B.S., MRCPsych, MSc. and her daughter Freya. 2003, NHS, North East LondonGoogle Scholar
  4. Committee on Drugs, American Academy of Pediatrics: The transfer of drugs and other chemicals into human milk. Pediatrics. 1994, 93 (1): 137-150.Google Scholar
  5. Austin M-P, Highet N, Guidelines Expert Advisory Committee: Clinical Practice Guidelines for Depression and Related Disorders - Anxiety, Bipolar Disorder and Puerperal Psychosis - in the Perinatal Periodcp A Guideline for Primary Care Professionals. I. 2011, beyondblue: the national depression initiative, MelbourneGoogle Scholar
  6. Viguera AC, Newport DJ, Ritchie J, Stowe Z, Whitfield T, Mogielnicki J, Baldessarini RJ, Zurick A, Cohen LS: Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry. 2007, 164 (2): 342-345. 10.1176/appi.ajp.164.2.342.View ArticlePubMedGoogle Scholar
  7. Moretti ME, Koren G, Verjee Z, Ito S: Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Ther Drug Monit. 2003, 25 (3): 364-366. 10.1097/00007691-200306000-00017.View ArticlePubMedGoogle Scholar
  8. Bogen DL, Sit D, Genovese A, Wisner KL: Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health. 2012, 15 (1): 69-72. 10.1007/s00737-012-0257-3.PubMed CentralView ArticlePubMedGoogle Scholar
  9. McDonald K, Amir LH, Davey M-A: Maternal bodies and medicines: a commentary on risk and decision-making of pregnant and breastfeeding women and health professionals. BMC Publ Health. 2011, 11 (Suppl 5): S5-10.1186/1471-2458-11-S5-S5.View ArticleGoogle Scholar
  10. Ugarriza DN: Postpartum depressed women's explanation of depression. J Nurs Scholarsh. 2002, 34 (3): 227-233. 10.1111/j.1547-5069.2002.00227.x.View ArticlePubMedGoogle Scholar
  11. Boath E, Bradley E, Henshaw C: Women's views of antidepressants in the treatment of postnatal depression. J Psychosom Obstet Gynaecol. 2004, 25 (3–4): 221-233.View ArticlePubMedGoogle Scholar
  12. Schirm E, Schwagermann MP, Tobi H, den Berg LT d J-v: Drug use during breastfeeding. A survey from the Netherlands. Eur J Clin Nutr. 2004, 58 (2): 386-390. 10.1038/sj.ejcn.1601799.View ArticlePubMedGoogle Scholar
  13. Matheson I, Kristensen K, Lunde PKM: Drug utilization in breast-feeding women. A survey in Oslo. Eur J Clin Pharmacol. 1990, 38: 453-459. 10.1007/BF02336683.View ArticlePubMedGoogle Scholar
  14. Gendron MP, Martin B, Oraichi D, Berard A: Health care providers' requests to Teratogen Information Services on medication use during pregnancy and lactation. Eur J Clin Pharmacol. 2009, 65 (5): 523-531. 10.1007/s00228-008-0611-6.View ArticlePubMedGoogle Scholar
  15. Chaves RG, Lamounier JA, César CC: Self-medication in nursing mothers and its influence on the duration of breastfeeding. J Pediatr (Rio J). 2009, 85 (2): 129-134. 10.1590/S0021-75572009000200008.View ArticleGoogle Scholar
  16. Friguls B, Joya X, Garcia-Algar O, Pallas CR, Vall O, Pichini S: A comprehensive review of assay methods to determine drugs in breast milk and the safety of breastfeeding when taking drugs. Anal Bioanal Chem. 2010, 397 (3): 1157-1179. 10.1007/s00216-010-3681-0.View ArticlePubMedGoogle Scholar
  17. Menon SJ: Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet. 2008, 277 (1): 1-13.View ArticlePubMedGoogle Scholar
  18. Chaves RG, Lamounier JA, Cesar CC: Association between duration of breastfeeding and drug therapy. Asian Pac J Trop Dis. 2011, 1 (3): 216-221. 10.1016/S2222-1808(11)60032-7.View ArticleGoogle Scholar
  19. Amir LH: Medicines and breastfeeding: information is available on safe use (Letter). Med J Aust. 2007, 186 (9): 485-PubMedGoogle Scholar
  20. Drugs and Lactation Database (LactMed).,
  21. Perinatal Psychotropic Medicine Information Service (PPMIS).,
  22. Hale T: Medications and Mothers' Milk. 2008, Hale Publishing L. P, Amarillo, Texas, 13Google Scholar
  23. Koren G: Medication Safety in Pregnancy & Breastfeeding: The Evidence-Based A-to-Z Clinician's Pocket Guide. 2007, McGraw Hill, New YorkGoogle Scholar
  24. Loke YC: Pregnancy and Breastfeeding Medicines Guide. 2010, The Royal Women's Hospital, Pharmacy Department, Melbourne, AustraliaGoogle Scholar
  25. Lawrence R, Schaefer C: General commentary on drug therapy and drug risk during lactation. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. Edited by: Schaefer C, Peters P, Miller RK. 2007, Elsevier, London, 609-620. 2View ArticleGoogle Scholar
  26. Pearlstein T, Howard M, Salisbury A, Zlotnick C: Postpartum depression. Am J Obstet Gynecol. 2009, 200 (4): 357-364. 10.1016/j.ajog.2008.11.033.PubMed CentralView ArticlePubMedGoogle Scholar
  27. di Scalea TL, Wisner KL: Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2009, 10 (16): 2593-2607. 10.1517/14656560903277202.View ArticlePubMedGoogle Scholar
  28. Hale TW, Kendall-Tackett K, Cong Z, Votta R, McCurdy F: Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med. 2010, 5 (6): 283-288. 10.1089/bfm.2010.0011.View ArticlePubMedGoogle Scholar


© Amir et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.